Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

4 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Komers, Radko
DUPLEX, NCT03493685 / 2016-005141-23: Study of Sparsentan in Patients With Primary Focal Segmental Glomerulosclerosis (FSGS) Jan 2023 - Jun 2023 : Top-line eGFR endpoint data from DUPLEX trial for focal segmental glomerulosclerosis Interim analysis from DUPLEX trial for focal segmental glomerulosclerosis Feb 2021 - Feb 2021: Interim analysis from DUPLEX trial for focal segmental glomerulosclerosis	Active, not recruiting	3	371	Europe, Canada, US, RoW	sparsentan, RE-021, Irbesartan, Irbesartan Tablets USP	Travere Therapeutics, Inc.	Focal Segmental Glomerulosclerosis	03/23	02/26
PROTECT, NCT03762850 / 2017-004605-41 / ACTRN12618001511224: A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy	Active, not recruiting	3	406	Europe, US, RoW	sparsentan, RE-021, irbesartan, Irbesartan Tablets USP, Dapagliflozin	Travere Therapeutics, Inc., Retrophin, Inc.	Immunoglobulin A Nephropathy	08/23	07/26
SPARTACUS, NCT05856760: A Study to Investigate Safety and Effect of Sparsentan in Combination With SGLT2 Inhibition in Participants With IgAN	Completed	2	48	US, RoW	Sparsentan, Filspari, RE-021	Travere Therapeutics, Inc.	Immunoglobulin A Nephropathy	10/24	10/24
EPPIK, NCT05003986 / 2021-000621-27: Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases	Recruiting	2	67	Europe, US	Sparsentan, RE-021	Travere Therapeutics, Inc.	Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis, Alport Syndrome	05/25	06/25